一项比较干扰素α-2b与表柔比星不同剂量水平及给药方案预防膀胱癌复发的前瞻性研究。
A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer.
作者信息
Serretta V, Pavone C, Corselli G, Pavone-Macaluso M
机构信息
Urological Clinic, University of Palermo, Italy.
出版信息
Anticancer Drugs. 1992 May;3 Suppl 1:19-23. doi: 10.1097/00001813-199205000-00005.
Abstract
A pilot study in 62 patients has been carried out to evaluate the combination of epirubicin and interferon (IFN)-alpha 2b using different doses and schedules of intravesical administration in the prevention of recurrence of bladder cancer. Preliminary results show greater prophylactic efficacy not only when higher doses of epirubicin and IFN-alpha 2b are used but also when a larger interval between instillation of the compounds was used.
摘要
一项针对62名患者的初步研究已经开展，旨在评估表柔比星与α-2b干扰素联合使用不同剂量和膀胱内给药方案在预防膀胱癌复发方面的效果。初步结果表明，不仅使用更高剂量的表柔比星和α-2b干扰素时，而且当两种化合物灌注之间的间隔时间更长时，预防效果更佳。
Zotero 插件